Parkinson's disease with dementia and dementia with Lewy body disease: Two syndromes, the same disease?

Psychogeriatrics

Volumn 6, Issue SUPPL. 1, 2006, Pages

  Sellal, François ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Dementia; Lewy body disease; Parkinson's disease

Indexed keywords

AMYLOID BETA PROTEIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CLOZAPINE; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; NEUROLEPTIC AGENT; PLACEBO; RIVASTIGMINE; SCOPOLAMINE; TRIHEXYPHENIDYL;

ALZHEIMER DISEASE; AMNESIA; ARTICLE; BRAIN DYSFUNCTION; BRAIN REGION; CELL LOSS; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CORRELATION ANALYSIS; DELUSION; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; FREQUENCY ANALYSIS; HALLUCINATION; HUMAN; LONGITUDINAL STUDY; LOW DRUG DOSE; MEMORY DISORDER; MOLECULAR GENETICS; MOTOR DYSFUNCTION; NERVE CELL LESION; NEUROBIOLOGY; PARKINSON DISEASE; PARKINSONISM; PATHOGENESIS; PRIORITY JOURNAL; PSYCHOSIS; SYMPTOMATOLOGY; SYNAPTIC TRANSMISSION; VISUAL HALLUCINATION;

EID: 33750296646     PISSN: 13463500     EISSN: 14798301     Source Type: Journal    
DOI: 10.1111/j.1479-8301.2006.00132.x     Document Type: Article

References (48)

1. Charcot JM. Leçons sur les maladies du système nerveux. Delahaye (Paris) 1875.
2. Brown RG, Marsden CD. Neuropsychology and cognitive function in Parkinson's disease: An overview. In: Marsden CD, Fahn S, eds. Movement Disorders 2. Boston: Butterworth, 1987; 99-123.
3. Reitan RM, Boll TJ. Intellectual and cognitive functions in Parkinson's disease. J Consult Clin Psychol 1971; 37: 364-369.
4. Pirozzolo FJ, Hansch EC, Mortimer JA, Webster DD, Kuskowski MA. Dementia in Parkinson's disease: A neuropsychological analysis. Brain Cogn 1982; 1: 71-83.
5. Lees AJ, Smith E. Cognitive deficits in the early stages of Parkinson's disease. Brain 1983; 106: 257-270.
6. Weingartner H, Burns S, Diebel R, Le Witt PA. Cognitive impairment in Parkinson's disease: Distinguishing between effort-demanding and automatic cognitive processes. Psychiatry Res 1984; 11: 223-235.
7. Flowers KA, Pearce I, Pearce JMS. Recognition memory in Parkinson's disease. J Neurol Neurosurg Psychiatry 1984; 47: 1174-1181.
8. Saint-Cyr JA, Taylor AE, Lang AE. Procedural learning and neostriatal dysfunction in man. Brain 1988; 111: 941-959.
9. Bowen FP, Hoehn MM, Yahr MD. Parkinsonism: Alterations in spatial orientation as determined by a route walking test. Neuropsychologia 1972; 10: 355-361.
10. Danta G, Hilton RC. Judgement of the visual vertical and horizontal in patients with parkinsonism. Neurology 1975; 25: 43-47.
11. Brown RG, Marsden CD. Visuospatial function in Parkinson's disease. Brain 1986; 109: 987-1002.
12. Flowers KA, Robertson C. The effects of Parkinson's disease on the ability to maintain a mental set. J Neurol Neurosurg Psychiatry 1985; 48: 517-529.
13. Dubois B, Pillon B. Cognitive deficits in Parkinson's disease. J Neurol 1997; 244: 2-8.
14. Aarsland D, Cummings JL, Larsen JP. Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease. Int J Geriatr Psychiatry 2001; 16: 184-191.
15. Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE. Association of REM sleep behavior disorder and neurodegenerative disease may reflect underlying synucleinopathy. Mov Disord 2001; 16: 622-630.
16. Cummings JF. Intellectual impairment in Parkinson's disease: Clinical, pathologic, and biochemical correlates. J Geriatr Psychiatry Neurol 1988; 1: 24-36.
17. Marttila RJ, Rinne UK. Epidemiology of Parkinson's disease in Finland. Acta Neurol Scand 1976; 53: 81-102.
18. Mayeux R, Denaro J, Hemenegildo N et al. A population-based investigation of Parkinson's disease with and without dementia: relationship to age and gender. Arch Neurol 1992; 49: 492-497.
19. Hugues TA, Ross HF, Musa S et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology 2000; 54: 1596-1602.
20. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: An 8-year prospective study. Arch Neurol 2003; 60: 387-392.
21. Hietanen M, Teräväinen H. The effect of age of disease onset on neuropsychological performance in Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 244-249.
22. Mayeux R, Stern Y, Rosenstein R et al. An estimate of the prevalence of dementia in idiopathic Parkinson's disease. Arch Neurol 1988; 45: 260-262.
23. Aarsland D, Tandberg E, Larsen JP, Cummings JL. Frequency of dementia in Parkinson's disease. Arch Neurol 1996; 53: 538-542.
24. Kosaka K, Mehraein P. Dementia-Parkinsonism syndrome with numerous Lewy bodies and senile plaques in cerebral cortex. Arch Psychiatr Nervenkr 1979; 226: 241-250.
25. Kosaka K, Iseki E. Clinicopathological studies on diffuse Lewy body disease. Neuropathology 2000; 1: 1-7.
26. Hurtig HI, Trojanowski JQ, Galvin J et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000; 54: 1916-1921.
27. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993; 50: 140-148.
28. Apaydin H, Ahlskog E, Parisi JE, Boeve BF, Dickson DW. Parkinson disease neuropathology. Later-developing dementia and loss of the levodopa response. Arch Neurol 2002; 59: 102-112.
29. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002; 125: 391-403.
30. Van Duinen SG, Lammers GJ, Maat-Schieman ML et al. Numerous and widespread alpha-synuclein-negative Lewy bodies in an asymptomatic patient. Acta Neuropathol (Berlin) 1999; 97: 533-539.
31. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nature-Reviews 2001; 2: 492-501.
32. Merdes AR, Hansen LA, Jeste DV et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 2003; 60: 1586-1590.
33. Poewe W, Berger W, Benke T, Schelosky L. High-speed memory scanning in Parkinson's disease: Adverse effects of levodopa. Ann Neurol 1991; 29: 670-673.
34. Press D, Mechanic D, Manoach D. Working memory deficits in Parkinson's disease resolve after consolidation. Mov Disord 2001; 16: S25.
35. Rinne JO, Rummukainen J, Paljarvi L et al. Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra. Ann Neurol 1989; 26: 47-50.
36. Javoy-Agid F, Agid Y. Is the mesocortical dopaminergic system involved in Parkinson's disease? Neurology 1980; 30: 1326-1330.
37. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003; 2: 229-237.
38. Candy JM, Perry RH, Perry EK et al. Pathological changes in the nucleus of Meynert in Alzheimer's disease and Parkinson's diseases. J Neurol Sci 1983; 59: 277-289.
39. Nakano I, Hirano A. Parkinson's disease: Neuron loss in the nucleus basalis without concomitant Alzheimer's disease. Ann Neurol 1984; 15: 415-418.
40. Perry EK, Irving D, Kerwin JM et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: Similarity to Parkinson's and distinction from Alzheimer's disease. Alzheimer Dis Assoc Disord 1993; 7: 69-79.
41. Tiraboschi P, Hansen LA, Alford M et al. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000; 54: 407-411.
42. Dubois B, Danze F, Pillon B, Cusimano G, Lhermitte F, Agid Y. Cholinergic-dependent cognitive deficits in Parkinson's disease. Ann Neurol 1987; 22: 26-30.
43. Dubois B, Pillon B, Lhermitte F, Agid Y. Cholinergic deficiency and frontal dysfunction in Parkinson's disease. Ann Neurol 1990; 28: 117-121.
44. Kauffer DI, Catt KE, Lopez OL, DeKosky ST. Dementia with Lewy bodies: response of delirium-like features to donepezil. Neurology 1998; 51: 1512.
45. McKeith I, Del Series T, Spano PF et al. Efficacy of rivastigmine in dementia with Lewy bodies: A randomized, double-blind, placebo-controlled international study. Lancet 2000; 356: 2031-2036.
46. Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509-2518.
47. Ravina B, Putt M, Siderowf A et al. Donepezil for dementia in Parkinson's disease: A randomized, double-blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005; 76: 934-939.
48. McKeith I, Mintzer J, Aarsland D et al. Dementia with Lewy bodies. Lancet Neurol 2004; 3: 19-28.